This book provides a comprehensive overview of several promising novel drug targets and approaches against arrhythmias, with particular emphasis placed on malignant ventricular arrhythmias. The individual chapters address a single treatment strategy written by a leading expert on the chapter, including arrhythmia mechanisms, kinase inhibitors, calcium and potassium channel targets, and atrial selective drugs.